Compare Alcon AG (ALC) vs American Express Co (AXP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs American Express Co — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while American Express Co trades at $335.75 (market cap $238.53B). The key difference: American Express Co is far larger — about 7.3× Alcon AG's market cap, and American Express Co pays the higher dividend (1.09%). Which is the better fit depends on your goals.
| ALC | AXP | |
|---|---|---|
Market Cap | $32.69B | $238.53B |
Sector | Health | Financials |
52-Week High | $92.22 | $384.82 |
52-Week Low | $62.02 | $292.27 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
AXP trades at $349.58, down 0.68% on the day, with a bullish technical outlook and strong fundamentals. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.13% margin. Recent earnings beat expectations in Q1 2026, and analyst consensus targets $376.36. The stock benefits from premium cardholder growth and strategic partnerships.
Outlook remains positive with mid-teens earnings growth potential, though risks include consumer spending sensitivity and competitive pressures. Institutional sentiment is mixed with 38.6% buy ratings. The current price near $350 offers upside to the consensus target, supported by operational cash flow strength and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →
